• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Phio Pharmaceuticals Corp.

    7/30/25 4:03:07 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHIO alert in real time by email
    DEFA14A 1 phio_defa14a.htm ADDITIONAL DEFINITIVE PROXY MATERIALS

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 14A

    PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐   Preliminary Proxy Statement
       
    ☐   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
         
    ☐   Definitive Proxy Statement
       
    ☒   Definitive Additional Materials
       
    ☐   Soliciting Material under §240.14a-12

     

    PHIO PHARMACEUTICALS CORP.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒   No fee required.
       
    ☐   Fee paid previously with preliminary materials.
       
    ☐   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

       

     

     

    www.investorvote.com/PHIO Easy Online Access — View your proxy materials and vote. Step 1: Step 2: Step 3: Step 4: Step 5: Go to www.investorvote.com/PHIO. Click on the icon on the right to view meeting materials. Return to the investorvote.com window and follow the instructions on the screen to log in. Make your selections as instructed on each screen for your delivery preferences. Vote your shares. Online Go to www.investorvote.com/PHIO or scan the QR code — login details are located in the shaded bar below. Stockholder Meeting Notice Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be Held on September 11, 2025. Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2025 proxy statement and annual report to shareholders are available at: 046C5B When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before August 28, 2025 to facilitate timely delivery. 2 N O T

     
     

    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.investorvote.com/PHIO. — Phone – Call us free of charge at 1 - 866 - 641 - 4276. — Email – Send an email to [email protected] with “Proxy Materials Phio Pharmaceuticals Corp.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, requests for a paper copy of proxy materials must be received by August 28, 2025. Stockholder Meeting Notice Dear Phio Pharmaceuticals Corp. Stockholder, The 2025 Annual Meeting of Stockholders of Phio Pharmaceuticals Corp. will be held on September 11, 2025 at 9:00 a.m. Eastern Time, virtually via the internet at meetnow.global/MVQDAFW. To access the virtual meeting, you must have the 15 - digit code that is printed in the shaded bar located on the reverse side of this form. You are receiving this communication because you owned shares of the Company on July 18, 2025, the record date, which entitles you to vote at the Annual Stockholder Meeting. Proxy materials are now available on the Internet. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommend a vote FOR all nominees, FOR Proposals 2 , 3 and 4 , and THREE YEARS for Proposal 5 : 1 . Election of Directors : 01 - Robert J . Bitterman 02 - Patricia A . Bradford 03 - Robert L . Ferrara 04 - Jonathan E . Freeman, Ph . D . 05 - Curtis A . Lockshin, Ph . D . 06 - David H . Deming 2. Ratification of Grant Thornton, LLP, as our independent registered public accounting firm for the fiscal year ending December 31, 2025. 3. Approval of an amendment and restatement of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 950,000. 4. Advisory vote to approve the compensation of Phio’s named executive officers. 5. Advisory vote to approve the frequency of future advisory votes on the compensation of Phio’s named executive officers. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE . To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card .

     
     

     

    You invested in PHIO PHARMACEUTICALS CORP and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on September 11, 2025. Get informed before you vote View the Annual Report, Notice & Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to August 28, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1 - 800 - 579 - 1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. *If you choose to vote these shares in person at the meeting, you must request a “legal proxy.” To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number Your Vote Counts! FLASHID - JOB# For complete information and to vote, visit www.ProxyVote.com Control # Ricky Campana P.O. Box 123456 Suite 500 51 Mercedes Way Edgewood, NY 11717 1 OF 322,224 148,294 2 30# Hextone, Inc. P.O. Box 9142 Farmingdale, NY 11735 XXXX XXXX XXXX XXXX PHIO PHARMACEUTICALS CORP 2025 Annual Meeting Vote by September 10, 2025 11:59 PM ET Vote in Person at the Meeting* September 11, 2025 9:00 AM EDT Virtually via the internet at: meetnow.global/MVQDAFW To access the virtual meeting, you must refer to the "Virtually Attending the Annual Meeting" section of the Proxy Statement.

     
     

    Voting Items Board Recommends For 1. Election of Directors Nominees: 1A Robert J. Bitterman For Patricia A. Bradford 1B For Robert L. Ferrara 1C For Jonathan E Freeman Ph.D 1D For Curtis A. Lockshin Ph.D 1E For David H. Deming 1F For 2. Ratification of Grant Thornton, LLP, as our independent registered public accounting firm for the fiscal year ending December 31, 2025. For 3. Approval of an amendment and restatement of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 950,000. For 4. Advisory vote to approve the compensation of Phio's named executive officers. Years 5. Advisory vote to approve the frequency of future advisory votes on the compensation of Phio's named executive officers. NOTE: Such other business as may properly come before the meeting or any adjournment thereof. THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com FLASHID - JOB# Control # XXXX XXXX XXXX XXXX 1.00000 322,224 148,294 Under New York Stock Exchange rules, brokers may vote “routine” matters at their discretion if your voting instructions are not communicated to us at least 10 days before the meeting . We will nevertheless follow your instructions, even if the broker’s discretionary vote has already been given, provided your instructions are received prior to the meeting date . PHIO PHARMACEUTICALS CORP 2025 Annual Meeting Vote by September 10, 2025 11:59 PM ET

     

     

    Get the next $PHIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHIO

    DatePrice TargetRatingAnalyst
    6/5/2025$14.00Buy
    H.C. Wainwright
    More analyst ratings

    $PHIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres & CEO Bitterman Robert J bought $4,840 worth of shares (2,000 units at $2.42), increasing direct ownership by 8% to 27,149 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    6/11/25 5:00:01 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ferrara Robert L bought $6,050 worth of shares (2,500 units at $2.42), increasing direct ownership by 19% to 15,666 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    6/11/25 4:59:45 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres & CEO Bitterman Robert J bought $4,125 worth of shares (1,500 units at $2.75), increasing direct ownership by 6% to 25,149 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    6/10/25 4:43:57 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

    Clinical trial advances for INSTASYL siRNA lead product candidate PH-7625th cohort enrolling patients in on-going clinical studyKing of Prussia, Pennsylvania--(Newsfile Corp. - August 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio today reported its financial results for the quarter ended June 30, 2025 and provided a business update.Recent Corporate UpdatesPH-762 Clinical ProgressPhio's ongoing Phase 1b dose escalation clinical trial (NCT 06014086) is designed to evaluate the safety and tolerability of neoadjuvant use of intratum

    8/14/25 4:15:00 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

    King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 928,596 shares of common stock of the Company originally issued in December 2024 and January 2025, having exercise prices between $2.00 and $3.00 per share. Warrants to purchase 100,000 shares of common stock at the existing exercise price of $2.00 per share will be exercised at their existing exercise price of

    7/25/25 3:04:00 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

    Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4 metastatic Merkel cell patientKing of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that pathologic results are available for four of the five patients treated in the fourth cohort. A complete pathologic response (100% tumor clearance) has been reported for one patient with cutaneous squamous cell carcinoma (cSCC). One patient with metastatic Merkel cell carc

    7/25/25 12:36:00 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    SEC Filings

    View All

    SEC Form DEFA14A filed by Phio Pharmaceuticals Corp.

    DEFA14A - Phio Pharmaceuticals Corp. (0001533040) (Filer)

    8/28/25 4:01:04 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Phio Pharmaceuticals Corp.

    424B3 - Phio Pharmaceuticals Corp. (0001533040) (Filer)

    8/27/25 5:04:25 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Phio Pharmaceuticals Corp.

    EFFECT - Phio Pharmaceuticals Corp. (0001533040) (Filer)

    8/25/25 12:15:29 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    Leadership Updates

    Live Leadership Updates

    View All

    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

    Registration Link for Presentation and live Q&A to take place, Monday, June 30, 2025 at 10:00 am ESTMarlborough, Massachusetts--(Newsfile Corp. - June 24, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were rep

    6/24/25 7:45:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

    Registration Link for Presentation and live Q&A to take place, Wednesday, May 7, 2025 at 2:00 pm ESTMarlborough, Massachusetts--(Newsfile Corp. - May 1, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Phio's presentation and live Q&A will take place on Wednesday, May

    5/1/25 7:45:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

    Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of Mr. David H. Deming to the Phio Board of Directors, effective Feb 19, 2025. Mr. Deming will immediately serve as a member of the Board's Nominating Committee. Following the appointment of Mr. Deming, the Board now comprises 6 directors, 5 of whom are independent."Mr. Deming's extensive experience in in the biopharma sector, both through his investme

    2/20/25 7:45:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Phio Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $14.00

    6/5/25 7:35:43 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Phio Pharmaceuticals with a new price target

    HC Wainwright & Co. reiterated coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously

    6/14/21 6:22:20 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Carson Lisa Cabott

    3 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    6/18/25 4:30:56 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres & CEO Bitterman Robert J bought $4,840 worth of shares (2,000 units at $2.42), increasing direct ownership by 8% to 27,149 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    6/11/25 5:00:01 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ferrara Robert L bought $6,050 worth of shares (2,500 units at $2.42), increasing direct ownership by 19% to 15,666 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    6/11/25 4:59:45 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp.

    SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

    11/13/24 11:20:45 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

    SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

    2/6/24 10:30:10 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

    SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

    2/8/23 6:07:04 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care